Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma
| Autor: | Marieke W. J. Louwman, Selin Tokez, Loes M. Hollestein, Marlies Wakkee, Wilner Christopher Kan, Antien L. Mooyaart, Z. C. Venables, Tamar Nijsten |
|---|---|
| Přispěvatelé: | Dermatology, Pathology |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Male
Oncology medicine.medical_specialty Skin Neoplasms business.industry Incidence Incidence (epidemiology) Hazard ratio Dermatology medicine.disease Cancer registry Metastasis SDG 3 - Good Health and Well-being Risk Factors Interquartile range Internal medicine Epidemiology Carcinoma Squamous Cell medicine Humans Cumulative incidence Histopathology Registries business |
| Zdroj: | Journal of the American Academy of Dermatology, 86(2), 331-338. Mosby Inc. |
| ISSN: | 0190-9622 |
| DOI: | 10.1016/j.jaad.2021.09.067 |
| Popis: | Background Cutaneous squamous cell carcinoma (cSCC) represents the most serious form of keratinocyte cancers because of its metastatic potential. Studies on nationwide incidence and disease-specific survival rates of metastatic cSCC (mcSCC) are lacking. Objective To investigate the cumulative incidence and disease-specific survival of patients with mcSCC in the Dutch population and assess patient-based risk factors. Methods We conducted a nationwide cancer registry study including all patients with the first cSCC in 2007 or 2008, using data from the Netherlands Cancer Registry, the nationwide network and registry of histopathology and cytopathology, and Statistics Netherlands. Cumulative incidence and Kaplan-Meier curves were calculated, and time-dependent Cox proportional hazards regression analyses were used. Results Of the 11,137 patients, metastases developed in 1.9% (n = 217). The median time to metastasis was 1.5 years (interquartile range 0.6-3.8 years). The risk factors were age (adjusted hazard ratio [aHR] 1.03, 95% CI 1.02-1.05), male sex (aHR 1.7, 95% CI 1.3-2.3), and immunosuppression (aHR [organ transplant recipient] 5.0, 95% CI 2.5-10.0; aHR [hematologic malignancy] 2.7, 95% CI 1.6-4.6). The 5-year disease-specific survival for patients with mcSCC was 79.1%. Limitations Only histopathologically confirmed mcSCCs were included. Conclusion About 2% of cSCCs metastasize, with higher risk for men, increasing age, and immunocompromised patients. Disease-specific survival for patients with mcSCC is high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect